Sarepta(SRPT) is biopharma developing a treatment for Duchenne Muscular Dystrophy disease. The company reported impressive interim results. Granted the study has a small patient population, however, the results are quite impressive nevertheless. The stock appreciated very significantly since the reporting the results. However, it is in my opinion that more appreciation potential still exists.